Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)

NCT03682055 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

14

Enrollment

INDUSTRY

Sponsor class

Stopped Lack of efficacy

Conditions

Nasopharyngeal Carcinoma
Nasopharyngeal Cancer

Interventions

DRUG: VK-2019

Sponsor

Cullinan Therapeutics Inc.

Collaborators

[object Object]